source
- MapLight’s schizophrenia pill hits primary endpoint but falls short of challenging BMS’s CobenfyMapLight Therapeutics reported results from its Phase 2 ZEPHYR trial of the oral muscarinic agonist ML-007C-MA in schizophrenia. The trial met its primary endpoint, showing a statistically signifi…
- FDA schedules advisory committee meetings for rejected Replimune melanoma drug and Capricor DMD cell therapyThe FDA announced that it will hold two advisory committee meetings this week to revisit investigational therapies that were previously turned down. One meeting will consider Capricor Therapeutics'…